Imaging outcome measures for progressive multiple sclerosis trials

Imaging markers that are reliable, reproducible and sensitive to neurodegenerative changes in progressive multiple sclerosis (MS) can enhance the development of new medications with a neuroprotective mode-of-action. Accordingly, in recent years, a considerable number of imaging biomarkers have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, de Stefano, Nicola, Barkhof, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Advancing Trial Design in Progressive Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650056/
https://www.ncbi.nlm.nih.gov/pubmed/29041865
http://dx.doi.org/10.1177/1352458517729456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650056/
https://www.ncbi.nlm.nih.gov/pubmed/29041865
http://dx.doi.org/10.1177/1352458517729456

Ejemplares similares